Posted by Michael Wonder on 07 Dec 2016
FDA approves Genentech’s Avastin (bevacizumab) plus chemotherapy for a specific type of advanced ovarian cancer
6 December 2016 - In the United States, Avastin is now approved for nine distinct uses across six different types of cancer.
Genentech today announced that the U.S. FDA has approved Avastin (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Women are said to have a ‘platinum-sensitive’ form of the disease if a relapse occurs six months or longer following the last treatment with a platinum-based chemotherapy.
